ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
A phase 2 trial of ABSK-011+BSC in hepatocellular carcinoma, run by Abbisko Therapeutics Co, Ltd, now recruiting.
Overview
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression is a phase 2 interventional study registered as NCT07327034 by Abbisko Therapeutics Co, Ltd, with 141 participants planned, started 2025-06-13 and due to reach its primary completion in 2027-06-30. Interventions recorded: ABSK-011+BSC and Placebo+BSC.
Similar pages
not linked directly; found by shared links- TrialA Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
Shares Abbisko Therapeutics and the tag pipeline.
- TrialA Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )
Shares Abbisko Therapeutics and the tag pipeline.
- TrialA Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
Shares Abbisko Therapeutics and the tag pipeline.
- TrialStudy of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
Shares Abbisko Therapeutics and the tag pipeline.
- TrialA Study of PTX-9908 Injection for Non-resectable HCC with TACE
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialGPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialEfficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma
Shares Hepatocellular carcinoma and the tag pipeline.